[{"id":"ef1fc14f-d06e-498a-b8ff-3fb093bed54d","acronym":"INIM Study","url":"https://clinicaltrials.gov/study/NCT02949570","created_at":"2021-01-18T14:29:09.297Z","updated_at":"2024-07-02T16:37:28.109Z","phase":"Phase 2","brief_title":"Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study","source_id_and_acronym":"NCT02949570 - INIM Study","lead_sponsor":"Hybrigenics Corporation","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • inecalcitol (TX-522)"],"overall_status":"Unknown status","enrollment":" Enrollment 54","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 04/01/2018","study_completion_date":" 04/01/2018","last_update_posted":"2016-10-31"}]